Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Markus F. Renschler(Princess Margaret Cancer Centre), J. Mezger(Heidelberg University), Martin Steins(Heidelberg University), Kristiaan Nackaerts(Heidelberg University), Robert M. Jotte(Texas Oncology), Leon Bosquée(Heidelberg University), Martin Reck(German Center for Lung Research), José Trigo(Heidelberg University), Paul Lorigan(University of Manchester), Frances A. Shepherd(Princess Margaret Hospital), Mark A. Socinski(Florida Hospital Cancer Institute), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Jeffrey A. Bubis(Heidelberg University), Shaoyi Li(St. Jude Children's Research Hospital), Wolfgang Schütte(Heidelberg University), Mary O’Brien(Royal Marsden Hospital), Philip Clingan(Heidelberg University), David R. Spigel(Human Genome Sciences (United States))
Cited by 344
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k